Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

ARS Pharmaceuticals (SPRY) Profit After Tax (2021 - 2025)

ARS Pharmaceuticals' Profit After Tax history spans 5 years, with the latest figure at -$41.3 million for Q4 2025.

  • For Q4 2025, Profit After Tax fell 182.76% year-over-year to -$41.3 million; the TTM value through Dec 2025 reached -$171.3 million, down 2241.76%, while the annual FY2025 figure was -$171.3 million, 2241.76% down from the prior year.
  • Profit After Tax for Q4 2025 was -$41.3 million at ARS Pharmaceuticals, up from -$51.2 million in the prior quarter.
  • Across five years, Profit After Tax topped out at $49.9 million in Q4 2024 and bottomed at -$51.2 million in Q3 2025.
  • The 5-year median for Profit After Tax is -$14.9 million (2023), against an average of -$13.6 million.
  • The largest annual shift saw Profit After Tax soared 796.62% in 2024 before it crashed 258.6% in 2025.
  • A 5-year view of Profit After Tax shows it stood at $45.8 million in 2021, then tumbled by 131.52% to -$14.4 million in 2022, then skyrocketed by 50.32% to -$7.2 million in 2023, then surged by 796.62% to $49.9 million in 2024, then crashed by 182.76% to -$41.3 million in 2025.
  • Per Business Quant, the three most recent readings for SPRY's Profit After Tax are -$41.3 million (Q4 2025), -$51.2 million (Q3 2025), and -$44.9 million (Q2 2025).